Rapamycin
Rising Prostate Specific Antigen (PSA)
Tyme, IncPhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Rising Prostate Specific Antigen (PSA) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
sm88 Tyme, Inc | Phase 1/2 | CCC |
VITPSO Tyme, Inc | Phase 1/2 | CCC |
PHENYTOIN Tyme, Inc | Phase 1/2 | CCC |
Same molecule, other indications
Rapamycin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →